Printer Friendly

PFIZER ANNOUNCES EXECUTIVE APPOINTMENTS

 PFIZER ANNOUNCES EXECUTIVE APPOINTMENTS
 NEW YORK, Jan. 23 /PRNewswire/ -- Edmund T. Pratt, Jr., chairman of


Pfizer Inc since 1972, will retire March 1 and become chairman emeritus. As announced last year, he will be succeeded as chairman by William C. Steere, Jr., president and chief executive officer. Pratt will continue to serve on the board of directors.
 "Pfizer is a great company" said Pratt. "I consider myself very privileged to have been in a leadership role for so long and I look forward to providing whatever help I can to the new team."
 The board also announced that effective the same date Edward C. Bessey and Jean-Paul Valles, Ph.D., have been elected vice chairmen and that Barry M. Bloom, Ph.D., Henry A. McKinnell, Ph.D., and Robert Neimeth will become executive vice presidents.
 "We look forward to continuing the momentum provided by Ed Pratt during his long and distinguished career as Pfizer's CEO and chairman", said Steere.
 The board of directors added, "Ed Pratt has done an outstanding job during his 20 years of heading Pfizer. Not only has the company had a tremendous growth in sales and earnings under his leadership, but the billions Ed Pratt has invested in research has assured Pfizer shareholders of what appears to be an equally promising future. He also has to be commended for the systematic and orderly manner in which he positioned the new executive team for the exciting challenges that lie ahead."
 Pratt was named president of Pfizer Inc in 1971 and elected chairman of the board and chief executive officer in 1972. Steere became president and chief executive officer of Pfizer Inc in 1991. Their biographies and those of Bessey, Valles, Bloom, McKinnell and Neimeth follow.
 Pfizer Inc is a diversified, research-based health care company with businesses in pharmaceuticals, hospital products, consumer products, animal health, and specialty chemicals and minerals.
 -0- 1/23/92
 /CONTACT: A.A. Biesada, 212-573-2055, or Rick Honey, 212-573-2051, both of Pfizer/
 /FIRST AND FINAL ADD - BIOGRAPHICAL INFORMATION TO FOLLOW/
 (PFE) CO: Pfizer Inc ST: New York IN: MTC SU: PER SM -- NY066 -- 2841 01/23/92 13:17 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 23, 1992
Words:356
Previous Article:PFIZER RAISES FIRST QUARTER 1992 DIVIDEND TO 37 CENTS
Next Article:ARCO CHEMICAL REPORTS YEAR-END RESULTS
Topics:


Related Articles
PFIZER NAMES BESSEY HEAD OF U.S. PHARMACEUTICALS; MCKINNELL BECOMES PRESIDENT OF HOSPITAL PRODUCTS
PFIZER-ENDOWED CHAIR AT DUKE UNIVERSITY WILL HONOR EDMUND T. PRATT JR.
PFIZER ANNOUNCES EXECUTIVE APPOINTMENTS.
ARMOUR PHARMACEUTICAL COMPANY APPOINTS TWO NEW EXECUTIVES
CYTRX CORPORATION ANNOUNCES APPOINTMENT OF VICE PRESIDENT, MEDICAL & REGUALTORY AFFAIRS
PFIZER ANNOUNCES NEW EXECUTIVE RESPONSIBILITIES; TOMBROS MOVES TO V.P. FOR INVESTOR RELATIONS, SCHULZE NAMED V.P. FOR CORPORATE STRATEGIC PLANNING,...
JACQUES F. REJEANGE NAMED PRESIDENT AND CHIEF OPERATING OFFICER OF STERLING WINTHROP INC.; APPOINTMENT SIGNALS COMPANY POISED FOR GROWTH
PHYTERA, INC. APPOINTS CHRISTOPHER J. PAZOLES, PH.D., VICE PRESIDENT OF RESEARCH; NAMES LI-AN YEH, PH.D., AS DIRECTOR OF BIOLOGICAL EVALUATION
CLOSING COMPLETED, SANOFI NAMES MANAGEMENT TEAM FOR PHARMACEUTICAL DIVISION
INCYTE PHARMACEUTICALS APPOINTS NEW BOARD MEMBER

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters